Nektar Therapeutics (NKTR) Financial Statements
Nektar Therapeutics (NKTR) reported trailing twelve-month revenue of $54.6M (down 27.2% year on year) and net income of -$157.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$233.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NKTRNektar TherapeuticsFollow NKTR — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.07 | 0.08 | 0.15 | 0.20 | 0.23 | 0.17 | 0.31 | 1.19 | 0.11 | 0.15 | 0.10 | 0.09 | 0.09 | 0.10 | 0.06 | 0.05 | |
| Gross profit | 0.05 | 0.05 | 0.11 | 0.17 | 0.20 | 0.14 | 0.28 | 1.17 | 0.09 | 0.13 | 0.08 | 0.07 | 0.06 | 0.07 | 0.06 | — | |
| Research & development | 0.13 | 0.15 | 0.19 | 0.15 | 0.18 | 0.20 | 0.27 | 0.40 | 0.43 | 0.41 | 0.40 | 0.22 | 0.11 | 0.12 | 0.12 | 0.13 | |
| Operating income | -0.12 | -0.14 | -0.12 | -0.02 | -0.03 | -0.11 | -0.06 | 0.69 | -0.44 | -0.43 | -0.45 | -0.38 | -0.26 | -0.11 | -0.14 | -0.14 | |
| Pre-tax income | -0.13 | -0.17 | -0.16 | -0.05 | -0.08 | -0.15 | -0.10 | 0.68 | -0.44 | -0.44 | -0.52 | -0.36 | -0.28 | -0.12 | -0.16 | -0.15 | |
| Income tax | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | 0.00 | |
| Net income | -0.13 | -0.17 | -0.16 | -0.05 | -0.08 | -0.15 | -0.10 | 0.68 | -0.44 | -0.44 | -0.52 | -0.37 | -0.28 | -0.12 | -0.16 | -0.16 | |
| Diluted EPS ($) | -1.19 | -1.50 | -1.40 | -0.42 | -0.61 | -1.10 | -0.62 | 56.70 | -37.80 | -37.35 | -42.90 | -29.55 | -21.75 | -8.68 | -9.73 | -4.76 | |
| Diluted shares (bn) | — | — | — | — | — | — | — | 0.012 | 0.012 | 0.012 | 0.012 | 0.012 | 0.013 | 0.014 | 0.017 | — |
USD billions · SEC XBRL
Nektar Therapeutics — questions
- What is Nektar Therapeutics's revenue?
- $54.6M over the twelve months to 2026-06-30, down 27.2% year on year, from its 10-Q and 10-K filings.
- What is Nektar Therapeutics's net income?
- -$157.1M over the twelve months to 2026-06-30.
- What is Nektar Therapeutics's free cash flow?
- -$233.3M over the twelve months to 2026-06-30.
- What are Nektar Therapeutics's diluted earnings per share?
- $-4.76 over the twelve months to 2026-06-30.
Every figure on this page comes from Nektar Therapeutics's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.